News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Sunascen Therapeutics Gets FDA's Green Light For The New Over-The-Counter NAUS-EASE® Tablets

4/24/2014 10:03:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

APRIL 23, 2014 Rockville, MD – Recently, the U.S. Food and Drug Administration (FDA) green-lighted over-the-counter NAUS-EASE® (Meclizine HCl) 25mg tablets for use as an antiemetic – to prevent and treat nausea and vomiting. NAUS-EASE® (Meclizine HCl) tablets are currently the only FDA reviewed and approved antiemetic available over the counter, providing up to 24 hour relief of nausea and vomiting with a single dose. This approval marks a key step in providing individuals who suffer from infrequent nausea and vomiting, access to a superior quality over the counter product that is trusted by doctors, pharmacists, and patients.

When it comes to over the counter medications and healthcare products, it is evident that consumers want to purchase a product for its quality and effectiveness, not just the manufacturing facility it comes from. Sunascen Therapeutics has been committed to developing and promoting superior quality products designed to improve and protect the consumer’s health. The addition of non-prescription NAUS-EASE® to the Sunascen Therapeutics product portfolio also marks the beginning of an expansive number of developing products and categories. “We want to assist consumers in managing their health needs by enabling them to select our products with confidence to meet those needs. Our goal is to develop products which exceed FDA requirements with a level of quality that remains unsurpassed by its competitors, especially for over the counter medications,” said Sandip Patel, CEO of Sunascen Therapeutics LLC.

We will continue to work closely with our retail partners to make NAUS-EASE® tablets available to consumers throughout the United States by year-end 2014.

For more information on NAUS-EASE®, please visit

About Sunascen Therapeutics LLC

At Sunascen Therapeutics, we apply extensively researched science and our technical resources to develop pharmaceutical and healthcare products, which are designed to ease suffering and enhance the quality of life. Consistent with our corporate strategy, corporate responsibility, and our consumer’s expectations, we value the discovery and development of quality healthcare products, diagnostic tools, and medical devices, both prescription and OTC. We aim to surpass the current standard for quality, safety and effectiveness.

Along with the advisory and management consulting services offered, Sunascen Therapeutics is continuously strengthening the product portfolio by searching for business partners interested in co-developing new pharmaceutical products that fit within, and complement our corporate and product development strategy. We develop strategic partnerships with existing, and emerging companies to develop and commercialize safe, effective, and innovative treatments for diseases which have insufficient treatment options or medical needs that remain unmet, including those of orphan diseases. We offer a full range of product development and support services designed to accelerate innovation and efficiently execute the approval process, new market entry, and support. Our entire production, operations, and corporate governance are based in the United States of America.

For more information on Sunascen Therapeutics LLC, please visit

Corporate Contact:
Sandip Patel
Chief Executive Officer
Sunascen Therapeutics LLC
(240) 403-2614


Statements in this press release include forward-looking statements regarding Sunascen Therapeutics LLC’s financial position and outlook, as well as Sunascen Therapeutics business. These forward-looking statements are based on current expectations, which involve assumptions, significant unforeseen uncertainties and risks, as well as potential changes in circumstances. Statements describing Sunascen Therapeutics goals, expectations, financial projections or other business related projections, intentions, beliefs, including the planned commercialization of any product, are considered forward-looking statement and shall be considered an at-risk statement. At-risk statements are subject to uncertainties, particularly those intrinsic to the discovery, development, and commercialization process for pharmaceutical and life science products, which are safe and effective for use as human therapies and in the venture of building a business around regulatory approved drugs. Furthermore, forward-looking statements discussed by Sunascen Therapeutics involve a certain degree of assumptions, which if never materialized nor proven correct, may possibly cause results to differ materially from those otherwise implied or expressed by such forward-looking statements. As a result, Sunascen Therapeutics advises the use of caution for forward-looking statements. Therefore, no assurance is implied or will be given to the outcomes stated in such forward-looking statements, and whether certain estimates will be achieved. Although forward-looking statements made by Sunascen Therapeutics emulate the good faith judgment of its management, these statements are based solely on factual information and factors currently known by Sunascen Therapeutics. The statements provided in this press release are based on the date of this release, and Sunascen Therapeutics assumes no commitment, and therefore explicitly declines any commitment to revise or update any forward-looking statements, resulting from future events, or new information.

In the above press release, unless the context specifies or requires otherwise, "Sunascen Therapeutics", "Company", "we", “us”, and "our" directly refer to Sunascen Therapeutics LLC. “Sunascen”, “Sunascen Therapeutics”, and “NAUS-EASE®” are trademarks of Sunascen Therapeutics LLC.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus